公开(公告)号：US20230265218A1

公开(公告)日：2023-08-24

申请号：US18172987

申请日：2023-02-22

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US20240218082A1

公开(公告)日：2024-07-04

申请号：US18440860

申请日：2024-02-13

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/468 ,  C07K16/2818 ,  C07K16/3069 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28 x anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28 x anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US20240391849A1

公开(公告)日：2024-11-28

申请号：US18736405

申请日：2024-06-06

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Joseph Erhardt ,  Rhys Salter ,  Theresa McDevitt

IPC: C07B59/00 ,  A61K39/00 ,  A61K51/10 ,  A61P35/00 ,  C07K16/30

Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

公开(公告)号：US20210017099A1

公开(公告)日：2021-01-21

申请号：US16955094

申请日：2018-12-17

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Joseph Erhardt ,  Rhys Salter ,  Theresa McDevitt

IPC: C07B59/00 ,  C07K16/30 ,  A61K51/10 ,  A61P35/00

Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

公开(公告)号：US12240790B2

公开(公告)日：2025-03-04

申请号：US16955094

申请日：2018-12-17

Applicant: Janssen Biotech, Inc.

Inventor： Vadim Dudkin ,  Shalom Goldberg ,  Joseph Erhardt ,  Rhys Salter ,  Theresa McDevitt

IPC: A61K39/00 ,  A61K51/10 ,  A61P35/00 ,  C07B59/00 ,  C07K16/30

Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.

公开(公告)号：US20230322961A1

公开(公告)日：2023-10-12

申请号：US18311771

申请日：2023-05-03

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.